GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medeon Biodesign Inc (ROCO:6499) » Definitions » EV-to-EBIT

Medeon Biodesign (ROCO:6499) EV-to-EBIT : -2.79 (As of Jun. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Medeon Biodesign EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Medeon Biodesign's Enterprise Value is NT$2,861.0 Mil. Medeon Biodesign's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-1,026.0 Mil. Therefore, Medeon Biodesign's EV-to-EBIT for today is -2.79.

The historical rank and industry rank for Medeon Biodesign's EV-to-EBIT or its related term are showing as below:

ROCO:6499' s EV-to-EBIT Range Over the Past 10 Years
Min: -27.47   Med: -8.68   Max: 60.82
Current: -2.8

During the past 12 years, the highest EV-to-EBIT of Medeon Biodesign was 60.82. The lowest was -27.47. And the median was -8.68.

ROCO:6499's EV-to-EBIT is ranked worse than
100% of 447 companies
in the Medical Devices & Instruments industry
Industry Median: 19.23 vs ROCO:6499: -2.80

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Medeon Biodesign's Enterprise Value for the quarter that ended in Mar. 2024 was NT$2,292.7 Mil. Medeon Biodesign's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was NT$-1,026.0 Mil. Medeon Biodesign's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -44.75%.


Medeon Biodesign EV-to-EBIT Historical Data

The historical data trend for Medeon Biodesign's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medeon Biodesign EV-to-EBIT Chart

Medeon Biodesign Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.82 -11.00 -7.49 -8.46 -8.78

Medeon Biodesign Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.78 -6.22 -2.48 -2.23 -2.23

Competitive Comparison of Medeon Biodesign's EV-to-EBIT

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's EV-to-EBIT falls into.



Medeon Biodesign EV-to-EBIT Calculation

Medeon Biodesign's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=2860.985/-1026.012
=-2.79

Medeon Biodesign's current Enterprise Value is NT$2,861.0 Mil.
Medeon Biodesign's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,026.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medeon Biodesign  (ROCO:6499) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Medeon Biodesign's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-1026.012/2292.740675
=-44.75 %

Medeon Biodesign's Enterprise Value for the quarter that ended in Mar. 2024 was NT$2,292.7 Mil.
Medeon Biodesign's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-1,026.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medeon Biodesign EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Medeon Biodesign's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Medeon Biodesign (ROCO:6499) Business Description

Traded in Other Exchanges
N/A
Address
No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.

Medeon Biodesign (ROCO:6499) Headlines

No Headlines